Publication Name	World Journal of Hepatology
Manuscript ID	13888
Country	China

Received	2014-09-05 18:05
Peer-Review Started	2014-09-06 12:07
To Make the First Decision	2015-01-08 14:11
Return for Revision	2015-01-13 14:09
Revised	2015-01-27 20:42
Second Decision	2015-02-10 16:21
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-02-12 14:46
Articles in Press	2015-02-12 14:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-04 10:49
Publish the Manuscript Online	2015-05-19 17:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Management of recurrent hepatocellular carcinoma after liver transplant
Manuscript Source	Invited Manuscript
All Author List	Kenneth SH Chok
Funding Agency and Grant Number
Corresponding Author	Kenneth SH Chok, MBBS, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China. kennethchok@gmail.com
Key Words	Hepatocellular carcinoma; Recurrence; Transarterial chemoembolization; Liver transplantation; Targeted therapy; Resection; Radiofrequency ablation; Transarterial radioembolization; Immunosuppression; Stereotactic body radiation therapy
Core Tip	The management of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) seems to be a losing battle. Nonetheless, tremendous efforts have been made to combat this deadly disease. Intrahepatic recurrence may be treated by resection, which has some survival benefits as shown by small clinical trials. Other kinds of therapy including high-intensity focused ultrasound (HIFU) ablation, radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are also in use. HIFU ablation has been shown to produce better results when compared with RFA and TACE. The efficacy of systemic and targeted therapies for multiple recurrences is under investigation. Early results have suggested that the combination of sorafenib with mammalian target of rapamycin inhibitors may be useful for treating recurrent HCC after LT.
Publish Date	2015-05-19 17:28
Citation	Chok KSH. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015; 7(8): 1142-1148
URL	http://www.wjgnet.com/1948-5182/full/v7/i8/1142.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i8.1142

Full Article (PDF)	WJH-7-1142.pdf
Full Article (Word)	WJH-7-1142.doc
Manuscript File	13888-Review.doc
Answering Reviewers	13888-Answering reviewers.pdf
Audio Core Tip	13888-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	13888-Conflict-of-interest statement.pdf
Copyright License Agreement	13888-Copyright assignment.pdf
Peer-review Report	13888-Peer-review(s).pdf
Scientific Misconduct Check	13888-Scientific misconduct check.pdf
Scientific Editor Work List	13888-Scientific editor work list.pdf